Studying the effect of N-acetylcysteine on PAP, CRP, Pro-BNP and symptoms caused by pulmonary hypertension in patients with heart failure

Assessment of the effectiveness of N-acetylcysteine on improving pulmonary systolic blood pressure, protein C reactive, pro- BNP, and the degree of dyspnea in patients with pulmonary hypertension and heart failure before and after treatment

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20260224068939N1

Enrollment

Registered

2026-05-20

Start date

2026-02-19

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary hypertension due to heart disease. Other secondary pulmonary hypertension

Interventions

Intervention group: Single-group clinical trial before and after treatment. 32 patients with pulmonary hypertension due to heart disease are treated with N-acetylcysteine ??600 mg every 12 hours for 3

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Pulmonary arterial hypertension and heart failure (heart failure patients with reduced ejection fraction, preserved left heart valve disease, cardiomyopathy, previous congenital diseases) sPAP =30

Exclusion criteria

Exclusion criteria: Dissatisfaction with medication for any reason at any stage of follow-up Pulmonary hypertension is a result of causes other than heart disease, such as lung disease, metabolic diseases, medications, infections, vascular collagen, etc.

Design outcomes

Primary

Measure	Time frame
CRP. Timepoint: At the beginning of the study and 3 months after treatment. Method of measurement: Laboratory based on milligrams per liter.;Dyspnea. Timepoint: At the beginning of the study and 3 months after treatment. Method of measurement: The patient rates their dyspnea from 1 to 10 before and after treatment.;6-minute walk test result. Timepoint: At the beginning of the study and 3 months after treatment. Method of measurement: Based on meters.;Pulmonary artery blood pressure. Timepoint: At the beginning of the study and 3 months after treatment. Method of measurement: Based on specialized echocardiography.;Pro-BNP. Timepoint: At the beginning of the study and 3 months after treatment. Method of measurement: Laboratory and unit picogram per milliliter.;Taking N-acetylcysteine. Timepoint: At the beginning of the study and 3 months after treatment. Method of measurement: Before and after consumption.;Right ventricular function. Timepoint: At the beginning of the study and 3 months after treatment. Method of measurement: Based on specialized echocardiography.;Age. Timepoint: Year. Method of measurement: Year calculation.;Gender. Timepoint: -. Method of measurement: Appearance.	—

Measure

Time frame

CRP. Timepoint: At the beginning of the study and 3 months after treatment. Method of measurement: Laboratory based on milligrams per liter.;Dyspnea. Timepoint: At the beginning of the study and 3 months after treatment. Method of measurement: The patient rates their dyspnea from 1 to 10 before and after treatment.;6-minute walk test result. Timepoint: At the beginning of the study and 3 months after treatment. Method of measurement: Based on meters.;Pulmonary artery blood pressure. Timepoint: At the beginning of the study and 3 months after treatment. Method of measurement: Based on specialized echocardiography.;Pro-BNP. Timepoint: At the beginning of the study and 3 months after treatment. Method of measurement: Laboratory and unit picogram per milliliter.;Taking N-acetylcysteine. Timepoint: At the beginning of the study and 3 months after treatment. Method of measurement: Before and after consumption.;Right ventricular function. Timepoint: At the beginning of the study and 3 months after treatment. Method of measurement: Based on specialized echocardiography.;Age. Timepoint: Year. Method of measurement: Year calculation.;Gender. Timepoint: -. Method of measurement: Appearance.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShima Mehrabi

Bagheiat-allah University of Medical Sciences

mehrabishima808@gmail.com+98 21 8805 0436

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026